目的 探讨多格列艾汀联合恒格列净治疗血糖控制不佳2型糖尿病的临床疗效。方法 选取2024年1月—2026年1月中国人民解放军联勤保障部队第904医院内分泌科收治的82例血糖控制不佳2型糖尿病患者，按随机数字法分为对照组与治疗组，每组各41例。对照组患者口服脯氨酸恒格列净片，10 mg/次，1次/d。治疗组在对照组的治疗基础上口服多格列艾汀片，75 mg/次，2次/d，早餐前和晚餐前1 h内服用。两组用药8周。观察两组疗效情况，比较两组胰岛抵抗指数（HOMA-IR）、胰岛β细胞功能指数（HOMA-β）、糖化血红蛋白（HbAlc）、空腹血糖（FBG）、饭后2 h血糖（2 h PG）、空腹胰岛素（FINS）、脂蛋白相关磷脂酶A2（LP-PLA2）、谷胱甘肽过氧化物酶（GSH-Px）、肿瘤坏死因子-α（TNF-α）、超氧化物歧化酶（SOD）水平。结果 治疗后，治疗组总有效率（95.12%）显著高于对照组（78.05%，P＜0.05）。治疗后，两组糖尿病患者HOMA-IR指数显著降低，而HOMA-β指数升高（P＜0.05）；治疗后，与对照组对比，治疗组HOMA-IR指数降低，且治疗组HOMA-β指数升高（P＜0.05）。治疗后，两组HbAlc、FBG、2 h PG、FINS均较同组治疗前显著降低（P＜0.05）；治疗后，与对照组对比，治疗组HbAlc、FBG、2 h PG、FINS指标降低，两组比较差异有统计学意义（P＜0.05）。治疗后，两组血清LP-PLA2、TNF-α较同组治疗前显著降低，而GSH-Px、SOD水平升高（P＜0.05）；治疗后，与对照组对比，治疗组LP-PLA2、TNF-α水平均降低，且治疗组GSH-Px、SOD水平均升高（P＜0.05）。结论 多格列艾汀与恒格列净协同治疗血糖控制不佳2型糖尿病效果明显，能有效控制患者血糖，并改善糖代谢相关指标的水平，促进胰岛功能恢复，值得借鉴与应用。

Objective To explore the clinical efficacy of dorzagliatin combined with henagliflozin in treatment of type 2 diabetes with poor glycemic control. Methods From January 2024 to January 2026, 82 patients with type 2 diabetes with poor blood glucose control who were admitted to the Endocrinology Department of The 904th Hospital of the Chinese People's Liberation Army Joint Logistics Support Force were selected, and they were randomly divided into control group and treatment group, with 41 cases in each group. Patients in control group were orally administered with Henagliflozin Proline Tablets, at a dosage of 10 mg each time, once daily. Patients in treatment group took Dorzagliatin Tablets orally in addition to treatment of control group, the dosage was 75 mg per time, twice daily, taken 1 h before breakfast and before dinner. Both groups were administered the medication for 8 weeks. The therapeutic effects of two groups was observed, and the levels of HOMA-IR, HOMA-β, HbAlc, FBG, 2 h PG, FINS, LP-PLA2, GSH-Px, TNF-α, and SOD in the two groups were compared. Results After treatment, the total effective rate of treatment group (95.12%) was significantly higher than that of the control group (78.05%, P < 0.05). After treatment, the HOMA-IR index of diabetic patients in both groups significantly decreased, but the HOMA-β index increased (P < 0.05). After treatment, compared with control group, the HOMA-IR index of treatment group decreased, and the HOMA-β index of the treatment group increased (P < 0.05). After treatment, HbAlc, FBG, 2 h PG, and FINS in both groups were significantly lower than those before treatment in same group (P < 0.05). After treatment, compared with control group, the indicators of HbAlc, FBG, 2 h PG, and FINS in treatment group decreased, and the difference between two groups was statistically significant (P < 0.05). After treatment, the serum LP-PLA2 and TNF-α levels of both groups were significantly lower than those before treatment in same group, but the GSH-Px and SOD levels increased (P < 0.05). After treatment, compared with control group, the LP-PLA2 and TNF-α levels of treatment group decreased, and the GSH-Px and SOD levels of treatment group increased (P < 0.05). Conclusion Dorzagliatin combined with henagliflozin has a significant effect in treatment of type 2 diabetes with poor blood glucose control, and can effectively control the blood sugar levels of patients, improve the levels of sugar metabolism related indicators, and promote the recovery of pancreatic function, which is worthy of reference and application.